Related Experiment Video
Updated: Nov 29, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor
Yuichi Shibui1, Kenichi Kohashi1, Akihiko Tamaki1
1Department of Anatomic Pathology Graduate School of Medical Sciences, Kyushu University, Maidashi3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan.
Purpose:
Malignant rhabdoid tumor (MRT) is a rare, highly aggressive sarcoma with an uncertain cell of origin. Despite the existing standard of intensive multimodal therapy, the prognosis of patients with MRT is very poor. Novel antitumor agents are needed for MRT patients. Forkhead box transcription factor 1 (FOXM1) is overexpressed and is correlated with the pathogenesis in several human malignancies. In this study, we identified the clinicopathological and prognostic values of the expression of FOXM1 and its roles in the progression of MRT.
Methods:
We investigated the FOXM1 expression levels and their clinical significance in 23 MRT specimens using immunohistochemistry and performed clinicopathologic and prognostic analyses. We also demonstrated correlations between the downregulation of FOXM1 and oncological characteristics using small interfering RNA (siRNA) and FOXM1 inhibitor in MRT cell lines.
Results:
Histopathological analyses revealed that primary renal MRTs showed significantly low FOXM1 protein expression levels (p = 0.032); however, there were no significant differences in other clinicopathological characteristics or the survival rate. FOXM1 siRNA and FOXM1 inhibitor (thiostrepton) successfully downregulated the mRNA and protein expression of FOXM1 in vitro and the downregulation of FOXM1 inhibited cell proliferation, drug resistance to chemotherapeutic agents, migration, invasion, and caused the cell cycle arrest and apoptosis of MRT cell lines. A cDNA microarray analysis showed that FOXM1 regulated FANCD2 and NBS1, which are key genes for DNA damage repair.
Conclusion:
This study demonstrates that FOXM1 may serve as a promising therapeutic target for MRT.
Insights
Forkhead box transcription factor 1 (FOXM1) is overexpressed in malignancies. Downregulating FOXM1 in malignant rhabdoid tumor (MRT) cells inhibited proliferation and drug resistance, suggesting FOXM1 as a potential therapeutic target for this aggressive sarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Malignant rhabdoid tumor (MRT) is a rare, aggressive sarcoma with poor prognosis.
- Novel therapeutic strategies are crucial for improving MRT patient outcomes.
- Forkhead box transcription factor 1 (FOXM1) is implicated in the pathogenesis of various human cancers.
Purpose of the Study:
- To investigate the clinicopathological and prognostic significance of FOXM1 expression in MRT.
- To elucidate the role of FOXM1 in MRT progression and its potential as a therapeutic target.
Main Methods:
- Immunohistochemistry was used to analyze FOXM1 expression in 23 MRT specimens.
- Clinicopathological and prognostic analyses were performed.
- Small interfering RNA (siRNA) and a FOXM1 inhibitor (thiostrepton) were used to downregulate FOXM1 in MRT cell lines.
- In vitro assays assessed the effects of FOXM1 downregulation on cell proliferation, drug resistance, migration, invasion, cell cycle, and apoptosis.
- cDNA microarray analysis identified FOXM1-regulated genes involved in DNA damage repair.
Main Results:
- Primary renal MRTs exhibited significantly lower FOXM1 protein expression.
- Downregulation of FOXM1 in MRT cell lines via siRNA or thiostrepton inhibited cell proliferation, chemoresistance, migration, and invasion.
- FOXM1 inhibition induced cell cycle arrest and apoptosis in MRT cell lines.
- FOXM1 was found to regulate FANCD2 and NBS1, key genes in DNA damage repair pathways.
Conclusions:
- FOXM1 plays a significant role in the progression of malignant rhabdoid tumors.
- FOXM1 inhibition demonstrates potential for therapeutic intervention in MRT.
- FOXM1 represents a promising therapeutic target for malignant rhabdoid tumors.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway

